Omission of breast surgery after neoadjuvant systemic therapy (NST) in select patients with invasive breast cancer may be feasible, according to a study published online March 28 in the Journal of the ...

Imagine a Texas where Alzheimer’s disease can be treated like diabetes. A $3 billion fund making its way through the ...

University of Houston at Sugar Land officials are set to complete construction in late June on its second academic building ...

Jeffrey Lee, MD, stepped into the role of chief medical executive Houston-based University of Texas MD Anderson Cancer Center ...

Yago Nieto, MD, PhD, discusses AFM13, how it works, and its effect as a bispecific antibody that targets CD30 and CD16.

Researchers are exploring strategies to alter the gut microbiome to improve patients’ responses to immunotherapy. New ...

At an April 1 meeting, Sugar Land City Council approved the first reading of an ordinance to rezone 8.041 acres from a single ...

The study results "signal unmet needs and potentially undertreated pain in patients with cancer,” researchers wrote.

Columbus-based OhioHealth has appointed George Simon, MD, as vice president of the system’s oncology services.  Before ...

CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ ...

CERo Therapeutics (CERO) announces its first clinical trial site for the Company’s Phase 1 clinical trial of CER-1236. The trial is focused on ...

If I had expected that scar, I probably would have waited to have it removed until after my wedding. I know that some scarring is simply the cost of doing business. But, I really wish I had known more ...